University of Texas Southwestern Medical Center
Dallas, Texas, 75239, United States
NCT Number: NCT02473536
To evaluate the safety and feasibility of pre-operative SABR of RCC IVC tumor thrombus.
To evaluate the effect of pre-operative SABR in RCC IVC tumor thrombus on relapse free survival at one year.
This study is active but is not currently recruiting participants.
Notify Me18 year and older
All sexes
Interventional
Phase 1 / Phase 2
Dallas, Texas, 75239, United States
Stereotactic Ablative Radiation Therapy (SABR): 5 fractions of 8 Gy or 3 fractions of 12Gy. The concept of stereotactic radiosurgery involves tightly conforming dose of therapeutic radiation confined to a small region of the body. This results in eradication or ablation of the target tumor with sparing of surrounding normal tissues. The largest experience with stereotactic radiosurgery is for the treatment of intracranial tumors Neoadjuvant treatment of IVC-TT with SABR may decrease local recurrences and lower the likelihood of embolic complications and systemic metastasis.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
10.1 A female of childbearing potential is any woman (regardless of sexual orientation, marital status, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:
Exclusion criteria
SABR
Time frame: 90 days
The treatment duration will be between 2-3 weeks depending on the fraction scheme chosen.
Time frame: 90 days
The treatment duration will be between 2-3 weeks depending on the fraction scheme chosen.
Time frame: ONE YEAR
Phase II To determine the relapse-free survival at one-year
Time frame: 90 days
To describe the associated peri-operative morbidity. Associated peri-operative morbidity is defined as grade>2 side effects as assessed by NCI's CTCAE v4.0 toxicity within one year of surgery.
Time frame: 1 year
To determine the associated adverse events within one year of surgery. Associated adverse events are any toxicity as defined by NCI's CTCAE v4.0 toxicity criteria for the first year post- surgery.
Time frame: 1 year
To determine the 1 year recurrence free survival
Time frame: 7 years
To determine the recurrence free survival
Time frame: 7 years
To determine the median time to recurrence
Time frame: 1 year
To determine the rate of pulmonary emboli within one year of surgery. Pulmonary Emboli: Pulmonary embolus determined in patients that become symptomatic and as a result has radiographic evidence of pulmonary embolus on CT angio or V/Q scan.
Time frame: 7 years
To determine the rate of pulmonary metastasis. Pulmonary Metastasis: Any evidence of new lung metastasis >1.0 cm
Time frame: 7 years
To determine the rate of systemic metastasis. Systemic Metastasis: Any evidence of new metastasis that is progressing on a second scan > 6 weeks apart
Time frame: 7 years
The rate of overall survival. Overall Survival: Time to death from the date of treatment start.
University of Texas Southwestern Medical Center
Other
Safety Lead-in Phase II Trial of Neo-adjuvant SABR for IVC Tumor Thrombus in Newly Diagnosed RCC
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04413123
Adenocarcinoma, Carcinoma
Boston, Massachusetts, United States
View Trial DetailsNCT02306954
Adenocarcinoma, Carcinoma
Portland, Oregon, United States
View Trial DetailsNCT05468697
Adenocarcinoma, Carcinoma
Washington D.C., District of Columbia, United States
View Trial DetailsNCT02867592
Adenocarcinoma, Adrenal Cortex Diseases
Birmingham, Alabama, United States
View Trial Details